scispace - formally typeset
M

Mirando Mrsić

Researcher at University of Zagreb

Publications -  41
Citations -  492

Mirando Mrsić is an academic researcher from University of Zagreb. The author has contributed to research in topics: Enzyme replacement therapy & Leukemia. The author has an hindex of 12, co-authored 41 publications receiving 459 citations.

Papers
More filters
Journal Article

Prostaglandin E2 for prophylaxis of oral mucositis following BMT.

TL;DR: It is shown that PGE is not effective for prophylaxis of oral mucositis in BMT recipients and the incidence of HSV infection was significantly higher in patients receiving PGE.
Journal Article

Total body irradiation with or without lung shielding for allogeneic bone marrow transplantation.

TL;DR: The results indicate that higher radiation dose to the lung did not increase antileukaemic efficacy of TBI but seemed to be associated with the increased pulmonary toxicity.
Journal ArticleDOI

Efficacy and safety of colistin in the treatment of infections caused by multidrug-resistant Pseudomonas aeruginosa in patients with hematologic malignancy: a matched pair analysis.

TL;DR: In patients with hematologic malignancies, colistin is effective in treating severe infections caused by MDR-PA while maintaining an acceptable toxicity profile, and prospective randomized studies comparing efficacy and safety ofcolistin with those of other antipseudomonal drugs are needed.
Journal Article

Surgical resection in the treatment of primary gastrointestinal non-Hodgkin's lymphoma: retrospective study.

TL;DR: In this article, the role of surgical resection in the treatment of patients with primary gastrointestinal non-Hodgkin's lymphoma was evaluated in a large-scale study.
Journal ArticleDOI

Acute promyelocytic leukemia M3: cytomorphologic, immunophenotypic, cytogenetic, and molecular variants.

TL;DR: The analysis of certain leukemic cell characteristics on the clinical outcome in APL revealed that patients with bcr3 had shorter medians of first remission and survival in comparison to patients with the bcr1 isoform of PML/RARalpha.